



21 December 2020

Dear Consumer

URGENT MEDICINE RECALL

TGA Ref Number: RC-2020-RN-01478-1

**TENOFOVIR DISOPROXIL EMTRICITABINE MYLAN 300/200 Aust R 265834
tenofovir disoproxil maleate 300mg and emtricitabine 200 mg film coated tablets**

ALL BATCHES WITHIN EXPIRY

Alphapharm Pty Ltd, following consultation with the Therapeutic Goods Administration (TGA), is initiating a consumer level recall of all batches within expiry of TENOFOVIR DISOPROXIL EMTRICITABINE MYLAN 300/200 tablets.

The consumer level recall is being requested as a precautionary measure due to the potential for broken and/or split tablets. In the event a broken/split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety.

Tenofovir Disoproxil Emtricitabine Mylan 300/200 is indicated for:

- The treatment of HIV-infected adults over the age of 18 years, in combination with other antiretroviral agents;
- In combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Patients that have been prescribed Tenofovir Disoproxil Emtricitabine Mylan 300/200 should consult their treating physician for individual advice.

Patients that have any units of unexpired stock should return them to their pharmacist for a refund.

Should you require any further information please contact 1800 274 276.

Thank you in advance for your support in this matter.

Mylan in Australia

Head Office

Level 1, 30 – 34 Hickson Rd, Millers Point, NSW 2000
P 02 9298 3999 F 02 9566 4686

Manufacturing & Human Resources

15 Garnet St, Carole Park QLD 4300
P 07 3000 6344 F 07 3000 6395

Toll Free Customer Service

P 1800 274 276

Alphapharm Pty Ltd (trading as Mylan Australia)

ABN 93 002 359 739

Mylan Health Pty Ltd

ABN 29 601 608 771

www.mylan.com.au

